Skip to main content
Colorado General AssemblyToggle Main Menu
Agency NameToggle Agency Menu
SB24-203

Prescription Drug Board Consider Rare Disease Advisory Council

Concerning requiring the Colorado prescription drug affordability review board to consider input from the Colorado rare disease advisory council under certain circumstances.
Session:
2024 Regular Session
Subject:
Insurance
Bill Summary

Current law requires the Colorado prescription drug affordability review board (board) to take certain measures in determining whether to conduct an affordability review for an identified prescription drug. The bill requires the board, in making such a determination, to consider whether the drug has an approved orphan drug designation for one or more rare diseases and no other indications and, if so, to consider input from consumers and the Colorado rare disease advisory council (council).

Current law requires the board, in performing an affordability review, to consider certain information. The bill requires the board to consider input from the council.


(Note: This summary applies to the reengrossed version of this bill as introduced in the second house.)

Status

Introduced
Passed
Became Law

Menu

Bill Text

  • All Versions (7 )
    Date Bill Type Documents
    06/06/2024 Signed Act PDF
    05/16/2024 Final Act PDF
    05/05/2024 Rerevised PDF
    05/04/2024 Revised PDF
    04/23/2024 Reengrossed PDF
    04/22/2024 Engrossed PDF
    04/08/2024 Introduced PDF

The effective date for bills enacted without a safety clause is August 7, 2024, if the General Assembly adjourns sine die on May 8, 2024, unless otherwise specified. Details